This could be a big breakthrough for people with peanut allergy’s.

Late-Breaking Peanut Patch Phase IIb Trial Results Unveiled at AAAAI Annual Meetinghttp://www.prweb.com/releases/2015/02/prweb12534466.htm

The 250 µg peanut patch shows the most promise for researchers. “After one year of therapy, half of the patients treated with the 250 ug patch tolerated at least 1 gram of peanut protein – about four peanuts —which is 10 times the dose that they tolerated in their entry oral peanut challenge,” Sampson explained.Overall, children treated with the 250 µg patch experienced a robust increase (19 fold) in peanut-specific IgG4 levels, the antibody associated with protection following immunotherapy.“EPIT appears safe, well tolerated and effective. That’s good news for families who suffer from food allergies,” Sampson said.